Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093933 · ClinicalTrials.gov registry record · Phase 3
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,106
- Enrollment target
NCT05093933: Completed Phase 3 study, sponsored by Merck Sharp & Dohme.
NCT05093933 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 6,106 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (691% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05093933, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
Primary Outcome
The time to first occurrence of the composite endpoint of CV death or HF hospitalization was defined as the time from randomization to the first event of CV death or HF hospitalization. Randomized participants without a HF hospitalization or CV death event at the time of analysis were censored at the last available information, when the protocol pre-specified number of total CV death events was achieved (primary completion analysis data cutoff), or the date of their non-CV death, whichever occur
Interventions
- DRUG Placebo
- DRUG Vericiguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,106 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 3 |
What the finished NCT05093933 record still lists
NCT05093933 is an interventional study that assigns participants to a tested intervention. Its 6,106 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (691% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05093933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05093933 about?
NCT05093933 is a clinical study titled "A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)". The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intra...
What is the current status of trial NCT05093933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,106 participants. The study started on 2021-11-02. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05093933?
The interventions under investigation include: Placebo (DRUG), Vericiguat (DRUG).
Who is sponsoring clinical trial NCT05093933?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05093933's enrollment target sits among peer trials
6,106 36th of 2000 higher than 1,965 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT06304168 · 6,150 participants
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
- NCT05884190 · 6,030 participants · NA
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI